How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
2 Dividend Stocks Worth Holding Forever (Including 1 Dividend King) A 50-year dividend grower and a monthly income REIT; how J&J and Realty Income build lasting wealth for patient investors.
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.
Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson. Even in a recession, there's strong demand for J&J's myriad of pharmaceutical and healthcare products.
Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way. Rising interest rates are unlikely to change the dynamics in the healthcare sector, where people are willing to pay for care.
3 of the Best ETFs to Buy and Hold if a Recession Is Coming VHT, BND, and VOO could be your best bets in the next economic downturn.
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.
Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue Jabil posted a double-beat quarter with nearly 29% revenue growth and 34% EPS growth, driven by AI demand, while maintaining buybacks and a Buy-rated analyst consensus.
